29th Jan 2024 12:35
Oxford BioMedica PLC - Oxfordshire, England-based gene and cell therapy - Completes purchase of ABL Europe SAS from Institut Merieux SA, cementing the partnership between Oxford BioMedica and Institut Merieux. ABL is a cell and gene therapy contract development and manufacturing organization with facilities in Lyon and Strasbourg in France. For the EUR15 million acquisition, Oxford BioMedica will issue 3.1 million new shares to Lyon-based Institut Merieux at a price of 407.4 pence, well above its current market price. This is a 3.2% stake, and Institut Merieux already had 3.3%, giving it a total 6.5% holding. Oxford BioMedica says Institut Merieux intends to raise this to 10.0% by the end of the September. Read More
